Laurence Albiges
Overview
Explore the profile of Laurence Albiges including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
275
Citations
12421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albiges L, Gross-Goupil M, Barthelemy P, Bamias A, Bedke J, Bex A, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39924391
Background And Objective: Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the...
2.
Bedke J, Ghanem Y, Albiges L, Bonn S, Campi R, Capitanio U, et al.
Eur Urol
. 2025 Feb;
PMID: 39904712
The KEYNOTE-564 trial showed that adjuvant immune checkpoint inhibitor (ICI) therapy with pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) and overall (OS) survival in localised clear-cell renal cell...
3.
Bex A, Jewett M, Lewis B, Abel E, Albiges L, Berg S, et al.
Eur Urol
. 2025 Jan;
PMID: 39855942
Neoadjuvant systemic treatment strategies have improved outcomes in several solid tumour types. This success has not yet been replicated in renal cell carcinoma (RCC). A consensus and international collaboration are...
4.
Maritaz C, Combarel D, Dalban C, Blondel L, Broutin S, Marabelle A, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39762076
Background: Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors;...
5.
Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, et al.
World J Urol
. 2025 Jan;
43(1):54.
PMID: 39747746
Purpose: Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% of...
6.
Margue G, Klein C, Parier B, Albiges L, Pignot G, Gravis G, et al.
Urol Oncol
. 2024 Nov;
PMID: 39603878
Background: Complete responses to immunotherapy in metastatic kidney cancer have led to a renewed interest in primary-site surgery. The prolonged survival of these patients has prompted consideration for nephron-sparing surgery...
7.
Powles T, Albiges L, Rini B
N Engl J Med
. 2024 Nov;
391(21):2062-2063.
PMID: 39602645
No abstract available.
8.
Bigot P, Boissier R, Khene Z, Albiges L, Bernhard J, Correas J, et al.
Fr J Urol
. 2024 Nov;
34(12):102735.
PMID: 39581661
Objective: To update the French recommendations for the management of kidney cancer. Methods: A systematic review of the literature was conducted for the period from 2014 to 2024. The most...
9.
Meade A, Frangou E, Choodari-Oskooei B, Larkin J, Powles T, Stewart G, et al.
Contemp Clin Trials Commun
. 2024 Nov;
42:101381.
PMID: 39555240
Clinical trials to establish the efficacy of new agents in the adjuvant cancer setting typically take many years to complete. During that time, external factors can impact recruitment and reporting...
10.
Barragan-Carrillo R, Saad E, Saliby R, Sun M, Albiges L, Bex A, et al.
Eur Urol
. 2024 Nov;
87(2):143-154.
PMID: 39505582
Background And Objective: The treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide...